Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update.
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will now be held in a virtual-only format by means of a live audio webcast at 3:00 p.m. CDT on Friday, May 29, 2020, instead of the location, time, and date previously disclosed in the proxy materials filed with the Securities and Exchange Commission on April 15, 2020. Stockholders will not be able to attend the Annual Meeting in person.
Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
These companies have a low financial burden Continue reading...
Savara has been struggling lately, but the selling pressure may be coming to an end soon.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Savara Inc. ("Savara" or "the Company") ...
A LLC for P. Terry's Burger Stand and a publicly traded pharmaceutical company are among those reporting new money. This list is often a gold mine for job seekers, salespeople and executives trying to keep tabs on the competition.
NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. ("Savara" or the "Company") (NASDAQ:SVRA). Such investors ...
Anyone researching Savara Inc. (NASDAQ:SVRA) might want to consider the historical volatility of the share price...
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Savara, Inc. (NASDAQ:SVRA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 PM Eastern ...
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday, March 12, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal ciprofloxacin). Also known as Linhaliq in Europe, Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis (NCFB).
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis (CF). Due to the COVID-19 pandemic, and out of an abundance of caution for people living with CF and clinical study staff, enrollment has been terminated in the Phase 3 AVAIL and the Phase 2a ENCORE studies. With patient safety at the forefront of the decision, and in accordance with guidelines established by the U.S. Food and Drug Administration (FDA), efforts will be made to allow enrolled patients to continue with study treatments and site visit protocols, where possible.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a business update.